Get started
Author

Saud Al Sifri

The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial
2011 · S. Al Sifri, A. Basiounny, et al. · International Journal of Clinical Practice · 104
Advancing Therapy in Suboptimally Controlled Basal Insulin–Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial
2021 · Julio Rosenstock, Rifat Emral, et al. · Diabetes Care · 68
A real-world study in patients with type 2 diabetes mellitus treated with gliclazide modified-release during fasting: DIA-RAMADAN
2020 · Mohamed Hassanein, Saud Al Sifri, et al. · Diabetes Research and Clinical Practice · 47
PDF
Direct and indirect health economic impact of hypoglycaemia in a global population of patients with insulin-treated diabetes
2018 · Ronnie Aronson, Gagik Galstyan, et al. · Diabetes Research and Clinical Practice · 31
PDF
Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin‐treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial
2021 · Rory J. McCrimmon, Saud Al Sifri, et al. · Diabetes Obesity and Metabolism · 29
PDF
The prevalence of cardiovascular disease in adults with type 2 diabetes mellitus in Saudi Arabia - CAPTURE study
2023 · Abdullah M. Alguwaihes, Amani Alhozali, et al. · Saudi Medical Journal · 25
PDF
Real-world safety and effectiveness of iGlarLixi in people with type 2 diabetes who fast during Ramadan: The SoliRam observational study
2023 · Mohamed Hassanein, Rachid Malek, et al. · Diabetes & Metabolic Syndrome Clinical Research & Reviews · 15
The Transcultural Diabetes Nutrition Algorithm: A Middle Eastern Version
2022 · Osama Hamdy, Saud Al Sifri, et al. · Frontiers in Nutrition · 12
Safety and Effectiveness of Concomitant iGlarLixi and SGLT-2i Use in People with T2D During Ramadan Fasting: A SoliRam Study Sub-analysis
2024 · Mohamed Hassanein, Rachid Malek, et al. · Diabetes Therapy · 11
PDF
Roadmap for the Management of Type 2 Diabetes and Hypertension in the Middle East: Review of the 2022 EVIDENT Summit
2023 · Yousef Al Saleh, Noor Al Busaidi, et al. · Advances in Therapy · 10
PDF
Filling the Knowledge Gap in Diabetes Management During Ramadan: the Evolving Role of Trial Evidence
2016 · Saud Al Sifri, Kashif Rizvi · Diabetes Therapy · 10
PDF
Optimizing Diabetes Management Using a Low-Calorie Diet in Saudi Arabia: A Cost-Benefit Analysis
2023 · Saud Al Sifri, Raed Aldahash, et al. · Diabetes Therapy · 6
PDF
Prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable coronary heart disease or an acute coronary syndrome in Saudi Arabia
2018 · Saud Al Sifri, Owayed Al Shammeri, et al. · Saudi Medical Journal · 6
Descriptive Regional Subanalysis of a Real-World Study in Patients with Type 2 Diabetes Treated with Gliclazide MR During Fasting: DIA-RAMADAN
2021 · Mohamed Hassanein, Saud Al Sifri, et al. · Diabetes Therapy · 5
PDF
Pharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan
2012 · Saud Al Sifri · Diabetes Metabolic Syndrome and Obesity · 4
PDF
Real-World Safety and Effectiveness of iGlarLixi in People With Type 2 Diabetes who Fast During Ramadan: Results From Wave 1 of the SOLIRAM Study
2021 · Mohamed Hassanein, Rakesh Kumar Sahay, et al. · Journal of the Endocrine Society · 3
PDF
The Use of Standardized Reporting and Time-in-Range in the Management of Diabetes: A Consensus Report
2021 · Saud Al Sifri, Adnan Alshaikh, et al. · International Journal of Clinical Medicine · 3
PDF
Summary of Research: Safety and Effectiveness of Concomitant iGlarLixi and SGLT-2i Use in People with T2D During Ramadan Fasting: A SoliRam Study Sub-analysis
2026 · Mohamed Hassanein, Rachid Malek, et al. · Diabetes Therapy · 2
PDF
Use of continuous glucose monitoring in non-intensively managed type 2 diabetes: a Saudi Arabian consensus
2026 · Mohammed Almehthel, Abdulghani Al-Saeed, et al. · Frontiers in Endocrinology · 2
PDF
Risk prediction and prevention in patients with advanced subclinical atherosclerosis
2026 · Michael J. Blaha, Abdulhalim J Kinsara, et al. · BMC Cardiovascular Disorders · 1
Phosphodiesterase type 5 inhibitors as treatment for erectile dysfunction: a webinar-based poll unveiling perceptions of healthcare professionals
2024 · Maher S Moazin, Abdulaziz Baazeem, et al. · Journal of Comparative Effectiveness Research · 1
Advancing Therapy in Suboptimally Controlled Basal Insulin-Treated Type 2 Diabetes: Clinical Outcomes with iGlarLixi versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial
2021 · Julio Rosenstock, Rifat Emral, et al. · 1
Abstract #1305594: Real-Life Effectiveness and Care Patterns of Diabetes Management in Eastern Europe, Middle East, and Africa (RECAP-DM EEMEA STUDY)
2022 · Adrian Sieberhagen, Khalid Tayeb, et al. · Endocrine Practice
Therapieintensivierung bei Typ-2-Diabetespatienten mit basalunterstützter oraler Therapie (BOT): Bessere klinische Ergebnisse mit iGlarLixi vs. BIAsp 30 in der SoliMix-Studie
2022 · Julio Rosenstock, Jochen Seufert, et al. · Diabetologie und Stoffwechsel
A Real-World Study in Patients with Type 2 Diabetes Treated with Gliclazide Modified Release during Fasting in Gulf Cooperation Council Countries: An Analysis from the International DIA-RAMADAN Study
2022 · Mohamed Hassanein, Saud Al Sifri, et al. · Dubai Diabetes and Endocrinology Journal
Works count: 32
Citation count: 396
H-index: 10
I10-index: 11
Year
Topic
Type